Aducanumab (Aduhelm), a new drug designed to treat Alzheimer's disease was approved by the FDA on June 7, 2021. RGA's Dr. Dave Rengachary discusses what this means for insurance, as well as the controversies around it.
In clinical practice differentiating Alzheimer’s from other conditions whose treatment is far different is important.
Dr. Achim Regenauer, Chief Medical Officer, discusses a newly published study that links air pollution to the occurrence of common neurodegenerative diseases, namely Alzheimer’s and Parkinson’s disease, the two fastest-growing neurological conditions in the world.
Could air pollution contribute to the risk of developing Alzheimer’s disease? Can mental stimulation and social connection protect against the cognitive decline? RGA's Hilary Henly explores lifestyle and environmental risk factors, explores genetic insights and testing advances and more.
Some of the articles featured in the September 2019 edition of RGA's Global Medical Newsletter include:
For a long time, Alzheimer’s could only be definitively diagnosed after a patient’s death based on neuropathological findings in the brain. Positron emission tomography (PET) scanning and spinal fluid technologies can improve on purely clinical diagnosis, but their cost and a lack of any cure means they are hardly used.
Slides from Dr. Brian Ivanovic’s presentation at the SOA Underwriting Issues & Innovations Seminar, Aug 1-2, 2016 in Chicago have been posted.
https://www.soa.org/Professional-Development/Event-Calendar/2016/underwr...
(Go to “Medical Topics” at the 8:05-9:40am time slot to download PDF)
Dementia is associated with growing old and has a devastating impact on individuals’ capacity to self-care. The organization Alzheimer’s Disease International projects there will be more than 75 million people with dementia worldwide by 2030.
http://www.genre.com/knowledge/blog/is-dementia-just-gradually-slowing-d...
